



IMMUNOLÓGIAI ÉS  
BIOTECHNOLÓGIAI  
INTÉZET



# 9th practice: Short and long term cell cultures, functional tests

Basic Immunology

University of Pécs, Clinical Center

Department of Immunology and Biotechnology

Pécs

# Main phases of medical research



In vitro  
experiment

Easy to **standardize** and  
reproduce



Mechanisms in living  
organisms are hard to  
estimate based on these data



In vivo animal  
experiment

Diseases can be **modelled**  
and drugs can be tested in  
complex organisms



Results cannot be directly  
extrapolated to humans



Human trial

Provides the **most  
relevant** medical data



**Difficult to conduct**  
(getting proper samples,  
ethical issues, etc.)

# Introduction to cell and tissue culturing<sup>[1.]</sup>

- Why is it necessary?
  - Reduces the numbers of animal experiments, if possible.
  - Experimental conditions are easy to control. (e.g. cell numbers, medium, temperature, concentration of the investigated substance, incubation times, etc.)

- Classification:



**Cell culture**


vs.



**Tissue or organ culture**


Stimulation →

Limited cell  
division



**Short term** cell culture (e.g.  
normal cells from a biopsy)

vs.



Unlimited cell  
division


**Long term** cell culture (e.g.  
cancerous cell line)

# Cell culturing

- Must be done under sterile conditions! → Contaminations (most notably microorganisms) make the experiments uncontrollable.
  - Manipulate cells in sterile hoods
  - Use sterile equipments (e.g. pipette tips, petri dishes, etc.)
  - Use of antibiotics in cell culturing mediums
- Cells are kept in cell **culturing mediums** which contain all the **nutrients** they require (carbohydrates, amino acids, nucleic acids, vitamins, hormones, growth factors, etc.) and have an **optimal pH**.
- **Incubators** are used for short-term storage which provide constant:
  - Temperature ( $\approx 37\text{ }^{\circ}\text{C}$ )
  - Humidity ( $\approx 90\%$ )
  - CO<sub>2</sub> content ( $\approx 5\text{-}6\%$ )
- Long-term storage (years, decades) of the cells is possible in **liquid nitrogen**.  
Application :
  - Preserving fertility in cancer patients who receive chemotherapy<sup>[2.]</sup>
  - Storage of hematopoietic stem cells from cord blood (not a routine process with some controversies<sup>[3, 4.]</sup>)

# Cell culturing sterile hood

**Laminar flow hoods** provide sterility by maintaining a constant unidirectional flow of filtered air.



In the case of the schematic hood shown above, air first passes through a **HEPA filter** (High Efficiency Particulate Air). Filtered, sterile air then flows from top to the bottom of the hood and eventually leaves towards the opening of the hood. The exact design varies and depends on the manufacturer.

# Frequently used culturing mediums



RPMI

(Roswell Park Memorial Institute)

Mainly used for culturing **lymphoid cells** and **hybridomas**.



DMEM

(Dulbecco's Modified Eagle's Medium)


A more generally used medium to culture **various cell types**. (fibroblasts, muscle cells, glia cells, neurons, etc.)

They usually contain phenol red **indicator**. → Used mediums which contain acidic waste products will turn yellow, whereas mediums with alkalic pH are purple.


# Cell lines 1.

## 1. HeLA cell line

- The **first** cancerous cell line established in 1951.<sup>[5.]</sup>
- Origin: Isolated from the cervical cancer (cervix adenocarcinoma) of the 31 years old **Henrietta Lacks** who died shortly afterwards in the same year.
- The cell line was established without her permission which lead to ethical issues when the entire genome of HeLa cells was published in 2013.<sup>[6.]</sup>
- Still one of the most **widely used** cell line in research.



HeLA cells



Dividing HeLA cell



Henrietta Lacks  
(1920-1951)

# Cell lines 2.

## 2. Jurkat cells

- Cancerous T cell line isolated from the peripheral blood of a 14 year old patient (JM) with acute lymphoblastic leukemia (ALL) in the 70s.<sup>[7.]</sup>
- It is used for investigating cell signaling in T cells, studying T cell derived leukemias and mechanisms of HIV infection.

## 3. Raji cells


- Cancerous B cell line isolated from a 11 years old patient's Burkitt lymphoma in Nigeria in 1963.<sup>[8.]</sup>
- It is EBV positive, the virus has integrated into the genome.<sup>[9.]</sup>
- Frequently used as a host for transfections.

## 4. HepG2 cells

- Isolated from the liver cancer (hepatocellular carcinoma) of a 15 years old patient.<sup>[10.]</sup>

## 5. Sp2 cells

- Non-secretory mouse myeloma cell line used to create hybridomas.<sup>[11.]</sup> → see 3rd practice




A group of Jurkat cells joined together



HepG2 cells


# Determination of cell viability

- It is usually done with **dye exclusion tests** such as:
  - **Trypan blue**
  - 7-aminoactinomycin D
  - Propidium-iodide
- Living cells tend to get rid off such xenobiotics with active mechanisms (e.g. efflux)



Living cells

Dead cells




Living cell

# Cell viability test


**Propidium iodide:** A fluorescent molecule that binds DNA which cannot cross the intact cell membranes of living cells.

**Annexin V:** It binds phosphatidylserine which can be found in the cell membranes of apoptotic cells.

Jurkat cells




Jurkat cells + camptothecin (chemotherapy)



# Isolation of mononuclear cells


- **Procedures based on physical parameters:**<sup>[19.]</sup>
  - Filtration (based on the different sizes of blood cells)
  - Density gradient centrifugation (e.g. **Ficoll gradient centrifugation**, based on the different density of blood cells)




- **Procedures based on leukocyte adherence:**
  - Nylon wool: monocytes and B cells will adhere to the nylon
  - Plastic/glass surfaces: monocytes will adhere to the surface, lymphocytes can be removed

# Ficoll gradient centrifugation 1.



Ordinary centrifugation:



Ficoll gradient centrifugation:



# Ficoll gradient centrifugation 2.




Peripheral blood mononuclear cells (**PBMC**, leukocytes with a non-segmented cell nucleus): **Lymphocytes, monocytes** (may also contain basophil granulocytes)<sup>[20.]</sup>

# Functional tests of phagocytes

- **Isolation:** Cells normally adhere to glass or plastic surfaces.
- **Migration:** Testing either spontaneous or directed (chemotaxis) cell migration in vitro or in vivo. (e.g. skin window test)
- **Phagocytosis :**
  - Non-opsonized
  - Opsonized (e.g. mediated through Fc receptors or complement receptors)
- **Respiratory burst and phagocytic enzymes:**
  - Nitroblue tetrazolium (NBT) test, myeloperoxidase (MPO) test, alkaline phosphatase test, lysozyme test, etc.
- **Testing cytokine production:**
  - ELISA, ELISPOT
  - CBA (Cytometric Bead Array): A multiplex flow cytometric method that relies on the use of microbeads

# Surface molecules of macrophages



# Skin window test<sup>[12.]</sup>



1. The **uppermost layer of the skin is removed** on the volar surface of the arm. (goal: being able to visualize capillaries without bleeding)



Skin window on the arm

2. A **filter paper** is put on the lesion. Depending on the experiment, it might contain **chemokins**. (such as IL-8)
3. The cells that migrate to the lesion will **leave the circulation** and enter the filter paper.
4. The filter paper is finally removed and its **cellular composition** is investigated.

Application: **In vivo investigation of cell migration**, e.g. comparing cell migration in healthy volunteers and patients with autoimmune disorders, etc.




The lesion heals without scars in a few days.


# Phagocytosis test

Method:


- **Labelled particles** (e.g. bacteria) are incubated together with phagocytes.
- Phagocytosis is then investigated under a microscope or with flow cytometry (for the latter → see 5th practice)




Video: A neutrophil granulocyte takes up several conidia.



Phagocytosis with fluorescence microscopy





Phagocytosis with immunohistochemistry





# Measuring phagocytosis

**A:** Untreated macrophages incubated without FITC-conjugated beads

**B:** Untreated macrophages incubated with FITC-conjugated beads




Treating the macrophages increased their phagocytosing capabilities.



**C:** Macrophages treated with plant polysaccharides incubated with FITC-conjugated beads


**D:** Macrophages treated with LPS incubated with FITC-conjugated beads

# NBT test



CGD patient

Healthy control




**Principle: Reactive oxygen species** reduce the dye which **turns blue**.<sup>[13.]</sup>


**Chronic granulomatous disease (CGD)**<sup>[14.]</sup>:

- An inherited **genetic disorder**, most often X-linked recessive.
- Innate immune cells can't produce reactive oxygen species. → They can't kill pathogens effectively. → **Primary immunodeficiency**
- **Recurrent bacterial and fungal infections** with granuloma formation in childhood.


# Respiratory burst



1. Phagocytosis (phagosome)  
↓
2. Phagosome + lysosome containing enzymes and reactive oxygen species  
→ **phagolysosome**  
↓
3. The enzymes and the reactive oxygen species kill the pathogen



Neutrophil




Pathogen  
bacterium




# Myeloperoxidase staining

- Myeloperoxidase is a characteristic enzyme of myeloid cells (most notably neutrophils) involved in the formation of reactive oxygen species.
- Detection of intracellular myeloperoxidase is important to confirm the **myeloid origin of certain leukemias**.<sup>[15, 16.]</sup>




Detection of myeloperoxidase in acute promyelocytic leukemia (AML-M3 or APL)



# Functional tests of lymphocytes


- **Polyclonal activation of lymphocytes:**
  - With plant lectins, e.g. phytohemagglutinin (PHA)
  - With bacterial cell wall components, e.g. lipopolysaccharide (LPS)
- **Testing cytotoxic activity (T and NK cells):**
  - Cr-51 release assay with isotope-labelled cells
  - Measuring the ratio of killed cells with flow cytometry (e.g. annexin V or propidium iodide staining<sup>[17.]</sup>)
- **Functional tests of B cells:**
  - Detection of immunoglobulin production (immunocytochemistry, ELISA)
  - Investigating genetic recombination of immunoglobulin genes with PCR
  - Plaque forming cell assay (PFC) → Testing of immunotoxicity
  - Passive cutaneous anaphylaxis test
- **Mixed lymphocyte culture:**
  - To rule out immunological incompatibility before transplantations
- **Testing cytokine production:**
  - ELISA, ELISPOT
  - CBA (Cytometric Bead Array)

# Steps of the CTL-mediated target cell killing:



1. Antigen recognition
2. Conjugation
3. CTL cytoplasmic rearrangement
4. CTL granule exocytosis
5. Apoptosis of target cell
6. Dissociation

# Mechanism of the CTL induced apoptosis



**Soluble effectors: perforins and granzymes**


**Membrane-bound effectors: Fas ligand (FAS-L)**

# Chrome-51 release assay

In vitro method for measuring the **cell killing capabilities** of cytotoxic cells (T, NK)<sup>[18.]</sup> and **ADCC**<sup>[19.]</sup> (Antibody-dependent cell-mediated cytotoxicity, see on the lectures), e.g.:

Investigating cytotoxic cells of cancer patients in the presence of cancer cells.

1. Tc cells are incubated together with Cr-51 labelled target cells
2. Target cell is killed, chrome is released
3. Centrifugation, cells and cell fragments form pellet at the bottom of the tube
4. The chrome content of the supernatant is measured



# Allergen-specific skin tests

IgE-mediated immediate reaction



Reading: 30 min

DTH:




Reading: 48h

# Contact allergy skin test




# Skin prick test (SPT)= in vivo allergen skin test

- More sensitive but less specific than the allergen-specific IgE measurement
- UK Allerge groups: dog, cat, dustmite, grass




# Mixed lymphocyte culture (MLC)



Application:

To check the **immunological incompatibility** of the donor and the recipient before transplantations.<sup>[21, 22.]</sup>

# Main subtypes of Th cells




- Th17 cells play an important role in **inflammatory disorders**. (see later)
- **Regulatory T cells** (Treg): They can inhibit other immune cells (**suppression**, see later), their immunophenotype is: **CD4<sup>+</sup>/CD25<sup>+</sup>/Foxp3<sup>+</sup>**


# CBA (Cytometric Bead Array)<sup>[23.]</sup>

- It is a **flow cytometric** method → see the 5th practice
- Principle: Molecules (e.g. DNA, proteins including immunoglobulins) can be specifically attached to the surface of **microbeads** that can be distinguished by different parameters such as size or fluorescence.
- Advantage: **Several different types of molecules** can be measured simultaneously **in a single sample** („multiplex measurement”), and it is **quantitative!**

Mixture of beads:




Investigation of the bead selected by  
its size or fluorescence  
(question: did it bind the antigen?)





# Distinguishing microbeads

Clustering based on size:




Clustering based on fluorescence:



It is most frequently used as a tool to measure the concentrations of various cytokines in a single sample. [23, 24]

# Luminex xMAP technology<sup>[25.]</sup>

Clustering of beads based on their fluorescence



Selection of relevant beads  
→


Further analysis of selected beads





Principle: Each bead contains the combination of 2 dyes, the ratio of the dyes however varies in each type of beads. E.g. the beads that have anti-IFN $\gamma$  antibodies on their surface contain more of the dye that gives signal in FL3 than the beads with anti-IL-6 antibodies. In theory more than 100 different types of beads can be measured simultaneously in a single sample.

# CBA analysis (measuring cytokines)

Gating the beads:



Clustering the beads:




- R2 = IL-8 → Negative
- R3 = IL-1β → Negative
- R4 = IL-6 → **Strong positivity**
- R5 = IL-10 → **Positive**
- R6 = TNFα → **Positive**
- R7 = IL-12p40 → Negative

## Quantitative measurement:

Levels of positivity can also be determined.

# Functional tests of the complement system

- Indication:
  - Recurrent infections due to **immunodeficiency**
  - **Autoimmune diseases**
- General test: based on **hemolysis** → CH50 or CH100<sup>[26,27]</sup>



CH50 → dilution of the sample which causes the hemolysis of 50% of RBC

CH100 → dilution of the sample which causes the hemolysis of 100% of RBC

# QuantiFERON®

Blood Test for the Detection of  
Latent Tuberculosis Infection






## Sampling tubes of QuantiFERON TB Gold Plus

	<p><b>NIL Tube</b></p> <ul style="list-style-type: none"><li>• Negative control</li><li>• Allows adjustment for background noise.</li></ul>
	<p><b>TB1 ANTIGEN Tube</b></p> <ul style="list-style-type: none"><li>• Includes <i>Mycobacterium tuberculosis</i> specific antigens ESAT-6 and CFP-10</li><li>• Peptides recognized by MHC Class II to detect CD4 response.</li></ul>
	<p><b>TB2 ANTIGEN Tube</b></p> <ul style="list-style-type: none"><li>• Includes <i>Mycobacterium tuberculosis</i> specific antigens ESAT-6 and CFP-10</li><li>• Peptides recognized by MHC Class I and II to detect CD4 and CD8 combined response.</li></ul>
	<p><b>Mitogen Tube</b></p> <ul style="list-style-type: none"><li>• Positive control</li><li>• Includes PHA and allows to check the functionality of the immune system</li><li>• Objectives:<ul style="list-style-type: none"><li>• To identify individuals with weakened immune system</li><li>• To validate specimen handling conditions</li></ul></li></ul>




# QuantiFERON-TB Gold Plus Protocol

## Step 1: Whole Blood incubation



**Nil Control**      **ESAT-6 CFP-10**      **Mitogen Control**

1) 1mL of whole blood (x4) and incubation at +37°C for 16-24 h.




2) 15 minutes Centrifugation


IFN- $\gamma$  is stable at 2-8° C for at least 4 weeks

## Step 2: INF- $\gamma$ ELISA testing


3) Add plasma and conjugate. Incubation 2H at room temperature



4) Wash then add Substrate. OD reading after 30 min.



5) Calculation and results printing





## Active and Latent Tuberculosis Infection

### TB-related morbidity and mortality

#### The TB pandemic – global emergency (1)

##### Active TB disease in 2013

- 9 million people developed TB disease
- 1.5 million people died

##### Latent TB infection (LTBI) in 2013

- 2 billion infected with *M. tuberculosis*
- 10% chance of developing active, contagious TB disease in their lifetimes

#### Screening and treatment (2)

2014 WHO guidelines, part of Broad strategy to “End TB” by 2035:

- Identify and treat LTBI for upper-middle and high income countries with TB incidence <100/100k population
- Screen and treat for LTBI in most at-risk populations for progression to active TB
- Reduce TB deaths by 95%; cut active TB cases by 90%

 As active TB rates decrease, LTBI diagnosis & preventive treatment grows in importance

1. WHO. Global tuberculosis report 2014. [http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1), Dec 1, 2014. 2. WHO. Guidelines on the management of latent tuberculosis infection. 2014 [http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1), Dec 1, 2014.



## From Latent TB infection to Active TB: Risk Factors

Risk factors to develop active TB form Latent TB infection	
Risk Factors	Estimation of relative risk*
AIDS	110 - 170
Well controlled HIV infection	50 - 110
Solid Organ Transplantation	20 - 74
Chronic Hemodialysis	10 - 25
Head and neck cancer	16
Recent tuberculosis infection (<2 years)	15
Systemic prolonged corticosteroids therapy	4.9
Anti-TNF $\alpha$ treatment	1.5 - 4
Diabetes	2 - 3.6
Malnutrition (body mass index < 20 kg/m <sup>2</sup> )	2 - 3
Passive smoking	2 - 3

\* Compared to a population without any risk factor

**HIV:** Human Immunodeficiency Virus

**TNF:** Tumor Necrosis Factor

Leroy H. et al in La revue du praticien vol. 62, avril 2012 p 484, adapted from Landry J, Menzies D. *Preventive chemotherapy. Where has it got us? Where to go next?* Int J Tuberc Lung Dis 2008;12:1352-64.

Sample to Insight

# References 1.

1. ThermoFischer Scientific: **Introduction to Cell Culture** (<https://www.thermofisher.com/hu/en/home/references/gibco-cell-culture-basics/introduction-to-cell-culture.html>)
2. Jensen JR<sup>1</sup>, Morbeck DE, Coddington CC 3rd: **Fertility preservation**. *Mayo Clin Proc*. 2011 Jan;86(1):45-9. doi: 10.4065/mcp.2010.0564.
3. Gluckman E<sup>1</sup>: **Family-directed umbilical cord blood banking**. *Haematologica*. 2011 Nov;96(11):1700-7. doi: 10.3324/haematol.2011.047050. Epub 2011 Jul 12.
4. Roura S<sup>1</sup>, et al.: **The role and potential of umbilical cord blood in an era of new therapies: a review**. *Stem Cell Res Ther*. 2015 Jul 2;6:123. doi: 10.1186/s13287-015-0113-2.
5. Lucey BP<sup>1</sup>, Nelson-Rees WA, Hutchins GM: **Henrietta Lacks, HeLa cells, and cell culture contamination**. *Arch Pathol Lab Med*. 2009 Sep;133(9):1463-7. doi: 10.1043/1543-2165-133.9.1463.
6. Hudson KL<sup>1</sup>, Collins FS: **Biospecimen policy: Family matters**. *Nature*. 2013 Aug 8;500(7461):141-2. doi: 10.1038/500141a.
7. Schneider U, Schwenk HU, Bornkamm G: **Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma**. *Int J Cancer*. 1977 May 15;19(5):621-6.
8. Drexler HG<sup>1</sup>, Minowada J: **History and classification of human leukemia-lymphoma cell lines**. *Leuk Lymphoma*. 1998 Oct;31(3-4):305-16.
9. Anvret M, Karlsson A, Bjursell G: **Evidence for integrated EBV genomes in Raji cellular DNA**. *Nucleic Acids Res*. 1984 Jan 25;12(2):1149-61.
10. Aden DP, et al.: **Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line**. *Nature*. 1979 Dec 6;282(5739):615-6.

# References 2.

11. Melixetian MB<sup>1</sup>, et al.: **Mouse myeloma cell line Sp2/0 multidrug-resistant variant as parental cell line for hybridoma construction.** *Hybrid Hybridomics*. 2003 Oct;22(5):321-7.
12. Marks DJ<sup>1</sup>, et al.: **Modified skin window technique for the extended characterisation of acute inflammation in humans.** *Inflamm Res*. 2007 Apr;56(4):168-74.
13. Freeman R, King B: **Technique for the performance of the nitro-blue tetrazolium (NBT) test.** *J Clin Pathol*. 1972 Oct;25(10):912-4.
14. Song E<sup>1</sup>, et al.: **Chronic granulomatous disease: a review of the infectious and inflammatory complications.** *Clin Mol Allergy*. 2011 May 31;9(1):10. doi: 10.1186/1476-7961-9-10.
15. Gluzman DF<sup>1</sup>, et al.: **Immunocytochemical markers in acute leukaemias diagnosis.** *Exp Oncol*. 2010 Sep;32(3):195-9.
16. van den Ancker W<sup>1</sup>, et al.: **A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin.** *Cytometry B Clin Cytom*. 2013 Mar;84(2):114-8. doi: 10.1002/cyto.b.21072. Epub 2013 Jan 16.
17. Zaritskaya L<sup>1</sup>, et al.: **New flow cytometric assays for monitoring cell-mediated cytotoxicity.** *Expert Rev Vaccines*. 2010 Jun;9(6):601-16. doi: 10.1586/erv.10.49.
18. Brunner KT, et al.: **Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.** *Immunology*. 1968 Feb;14(2):181-96.
19. Nelson DL<sup>1</sup>, Kurman CC, Serbousek DE: **51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC).** *Curr Protoc Immunol*. 2001 May;Chapter 7:Unit 7.27. doi: 10.1002/0471142735.im0727s08.
20. Poulsen OM, Hau J: **Murine passive cutaneous anaphylaxis test (PCA) for the 'all or none' determination of allergenicity of bovine whey proteins and peptides.** *Clin Allergy*. 1987 Jan;17(1):75-83.

# References 3.

21. Cerilli J, et al.: **The significance of mixed lymphocyte culture in related renal transplantation.** *Surgery.* 1980 Nov;88(5):631-5.
22. Mickelson EM<sup>1</sup>, et al.: **Evaluation of the mixed lymphocyte culture (MLC) assay as a method for selecting unrelated donors for marrow transplantation.** *Tissue Antigens.* 1996 Jan;47(1):27-36.
23. Moncunill G<sup>1</sup>, Campo JJ, Dobaño C: **Quantification of multiple cytokines and chemokines using cytometric bead arrays.** *Methods Mol Biol.* 2014;1172:65-86. doi: 10.1007/978-1-4939-0928-5\_6.
24. Prabhakar U<sup>1</sup>, et al.: **Multiplexed cytokine sandwich immunoassays: clinical applications.** *Methods Mol Med.* 2005;114:223-32.
25. Zhang Y<sup>1</sup>, Birru R, Di YP: **Analysis of clinical and biological samples using microsphere-based multiplexing Luminex system.** *Methods Mol Biol.* 2014;1105:43-57. doi: 10.1007/978-1-62703-739-6\_4.